Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 0.51 |
| ▸ | DRD3 | P35462 | 3/20 | 0.51 |
| ▸ | DRD4 | P21917 | 2/20 | 0.51 |
| ▸ | DRD5 | P21918 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 9/20 | 0.50 |
| ▸ | HTR1A | P08908 | 8/20 | 0.50 |
| ▸ | HTR2A | P28223 | 6/20 | 0.50 |
| ▸ | HTR6 | P50406 | 5/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6999266 | 0.92 | DRD2 (0.47) | DRD2DRD3DRD4DRD5HTR7 | |
| SCHEMBL6995810 | 0.90 | DRD2 (0.40) | DRD2DRD3DRD4DRD5HTR7 | |
| SCHEMBL6996001 | 0.90 | HTR7 (0.49) | DRD2DRD3DRD4HTR7HTR1A | |
| SCHEMBL6998180 | 0.88 | HTR7 (0.47) | DRD2DRD3DRD4DRD5HTR7 | |
| SCHEMBL6987487 | 0.88 | DRD2 (0.52) | DRD2DRD3DRD4HTR7HTR1A | |
| SCHEMBL6996880 | 0.86 | DRD2 (0.46) | DRD2DRD3DRD4DRD5HTR7 | |
| SCHEMBL6998560 | 0.85 | HTR7 (0.42) | DRD2DRD3DRD4DRD5HTR7 | |
| SCHEMBL6994472 | 0.85 | DRD2 (0.44) | DRD2DRD3DRD4DRD5HTR7 | |
| SCHEMBL6991304 | 0.84 | HTR1A (0.46) | DRD2DRD3DRD4HTR7HTR1A | |
| SCHEMBL6996279 | 0.84 | HTR7 (0.45) | DRD2DRD3DRD4DRD5HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6664251-B2 | Serotonin receptor antagonist; treating cardiovascular disorder | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2003-12-16 | — | — | US | disclosed |
| EP-0686632-B1 | BENZOTHIAZINE DERIVATIVE | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2003-08-06 | — | — | EP | disclosed |
| US-20030078256-A1 | Benzothiazine derivative | SUNTORY LIMITED (JP) | 2003-04-24 | — | — | US | disclosed |
| US-6001827-A | Benzothiazine derivative | SUNTORY LIMITED (JP) | 1999-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078256-A1 | Benzothiazine derivative | TPH2, ADRB2, TPH1 | DRD2 402/4885DRD3 341/4885DRD4 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.